Skip to Content

Acalabrutinib (Calquence®) In Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Download PQI pdf 0.16MB

Last Updated: March 12, 2023

By: Trey McNiel, PharmD

About this PQI

The purpose of this PQI is to discuss the clinical considerations around the use of acalabrutinib (Calquence®) to optimize the outcomes for patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI